Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

News & Events

$3.4 million funding boost supercharges fight against RSV

National research led by the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, has secured more than $3.4 million to assess the epidemiology of respiratory syncytial virus (RSV) throughout the country and optimise Australia’s immunisation strategy.

News & Events

Australia’s first DNA-based COVID-19 vaccine study set to begin at The Kids Research Institute Australia

Australia’s first needle-free, gene-based COVID-19 vaccine study will be spear-headed in WA by The Kids Research Institute Australia thanks to almost $6 million in Coronavirus Research Response funding announced by Health Minister Greg Hunt.

News & Events

The hidden burden of diabetes

When Jodie and Brad Scott welcomed their fourth child Heath into the world, they were prepared for the many sleepless nights that come with caring for newborns.

News & Events

Ear infections linked to passive smoking

A new report from Perth's The Kids for Child Health Research has found a strong link between childhood ear infections and exposure to tobacco smoke.

Research

Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study

In mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.

Research

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy

Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions.

Research

Mapping Drug-Resistant Tuberculosis Treatment Outcomes in Hunan Province, China

Drug-resistant tuberculosis (DR-TB) remains a major public health challenge in China, with varying treatment outcomes across different regions. Understanding the spatial distribution of DR-TB treatment outcomes is crucial for targeted interventions to improve treatment success in high-burden areas such as Hunan Province. This study aimed to map the spatial distribution of DR-TB treatment outcomes at a local level and identify sociodemographic and environmental factors associated with poor treatment outcomes in Hunan Province, China.

Research

Severe outcomes of malaria in children under time-varying exposure

In malaria epidemiology, interpolation frameworks based on available observations are critical for policy decisions and interpreting disease burden. Updating our understanding of the empirical evidence across different populations, settings, and timeframes is crucial to improving inference for supporting public health.

Research

Enablers and barriers to primary health care access for Indigenous adolescents: a systematic review and meta-aggregation of studies across Australia, Canada, New Zealand, and USA

Indigenous adolescents access primary health care services at lower rates, despite their greater health needs and experience of disadvantage. This systematic review identifies the enablers and barriers to primary health care access for Indigenous adolescents to inform service and policy improvements.

Research

Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study

Drug-resistant tuberculosis (DR-TB) is a major public health threat in Hunan Province, with an increasing clinical burden in recent years. This study aimed to identify socio-demographic and clinical factors associated with DR-TB in Hunan province, China.